| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4450214
Max Phase: Preclinical
Molecular Formula: C26H32FN3O4
Molecular Weight: 469.56
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: C#CCN(Cc1ccc(F)cc1)c1ccc(NC(=O)OC(C)(C)C)c(NC(=O)OC(C)(C)C)c1
Standard InChI: InChI=1S/C26H32FN3O4/c1-8-15-30(17-18-9-11-19(27)12-10-18)20-13-14-21(28-23(31)33-25(2,3)4)22(16-20)29-24(32)34-26(5,6)7/h1,9-14,16H,15,17H2,2-7H3,(H,28,31)(H,29,32)
Standard InChI Key: RWGLOYVKHMTDFT-UHFFFAOYSA-N
Associated Targets(Human)
Voltage-gated potassium channel subunit Kv7.4 100 Activities
Voltage-gated potassium channel subunit Kv7.5 49 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Voltage-gated potassium channel subunit Kv7.2 268 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 469.56 | Molecular Weight (Monoisotopic): 469.2377 | AlogP: 6.16 | #Rotatable Bonds: 6 |
| Polar Surface Area: 79.90 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 12.26 | CX Basic pKa: | CX LogP: 6.00 | CX LogD: 6.00 |
| Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.50 | Np Likeness Score: -1.24 |
References
| 1. Wang L, Qiao GH, Hu HN, Gao ZB, Nan FJ.. (2019) Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity., 10 (1): [PMID:30655942] [10.1021/acsmedchemlett.8b00315] |
Source
Source(1):